key: cord-1046378-8eh53zxk
authors: Contou, Damien; Fraissé, Megan; Pajot, Olivier; Tirolien, Jo-Anna; Mentec, Hervé; Plantefève, Gaëtan
title: Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?
date: 2021-01-04
journal: Crit Care
DOI: 10.1186/s13054-020-03449-6
sha: 90014b3d3407dc4579d842af01f585a2841611b9
doc_id: 1046378
cord_uid: 8eh53zxk

nan

As many countries in Europe, France faced a second wave COVID-19 pandemic since September, 2020. During the first wave, intensivists faced an unprecedented massive admission of patients with COVID-19 pneumonia requiring invasive mechanical ventilation, sometimes leading to ICUs saturation. They discovered the stereotypical course of this previously unknown disease with its own specificities including the need for deep sedation and neuromuscular blockade, the increased risk of thrombotic and hemorrhagic events [1, 2] , and the prolonged duration of mechanical ventilation [3] with high rate of delirium [4] . Importantly, several randomized controlled trials conducted during this first wave highlighted the beneficial effects of early administration of glucocorticoids for critically ill COVID-19 patients [5, 6] .

One can legitimately assume that the experience gained during the first wave may have contributed to a better management and outcome among critically ill COVID-19 patients admitted during the second wave.

We therefore compared the characteristics and the outcome between patients admitted to our 41-bed COVID-19 ICU for acute respiratory failure due to COVID-19 (RT-PCR positive for SARS-CoV-2) during the first wave (from March 13th to May 27th, 2020) and those admitted to our 18-bed ICU during the second wave (from August 19th to December 7th, 2020).

COVID-19 patients without acute respiratory failure, those transferred to other ICUs or still hospitalized in ICU were not included.

Eighty-two patients were admitted during the first wave and 50 during the second wave. Comparison between first and second wave regarding patients' characteristics, ICU scores, comorbidities, biological data, administered treatments and outcome is detailed in the Table 1 . Patients did not differ between the two waves with similar age, ICU scores and comorbidities. Contrary to the first wave, all the patients admitted during the second wave received early glucocorticoids and intermediate or full-dose thromboprophylaxis at ICU admission.

Compared to the first wave, we observed a lower proportion of patients requiring invasive mechanical ventilation and a lower rate of thrombotic events. The delay between ICU admission and tracheal intubation was longer during the second wave. ICU mortality (50% vs. 52%, p = 0.96) and duration of ICU stay did not differ between the two waves.

The Kaplan-Meier survival analysis did not show significant difference between the two waves (p = 0.90, logrank test) (Fig. 1) .

We herein report the first study comparing the outcome of critically ill COVID-19 patients between first and second wave in France. Despite a better understanding of COVID-19 with significant treatment Open Access However, patients admitted during the second wave were less likely to require invasive mechanical ventilation with a longer delay between ICU admission and tracheal intubation, potentially related to early administration of glucocorticoids [6] . However, this longer delay questions about the higher, albeit not statistically significant, ICU mortality observed in our intubated patients during the second wave.

The lower rate of thrombotic events observed during the second wave is likely inherent to the increased intensity of thromboprophylaxis even if a lower rate of CT pulmonary angiographies during the second wave cannot be ruled out.

The strengths of our study include the similar typology and severity of the patients during both waves making relevant the comparison. Its monocenter design, implying similar criteria of ICU admission and similar criteria of tracheal intubation by the same team of intensivists during both periods, may also be considered as a strength.

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Kaplan-Meier survival estimates during the 30 days following ICU admission of COVID-19 patients admitted during the first wave (blue curve) and the second wave (red curve) • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year research ? Choose BMC

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We warmly acknowledge Dr Elsa Logre, Dr Radj Cally, Dr Olivia Picq, Dr Florence Sarfati, Dr Paul Desaint and all the residents who took care of the patients.

Author's contributions DC is responsible for the conception and design. All the authors took care of the patients. DC and MF are responsible for data acquisition. All the authors were responsible for analysis and interpretation of data. All authors read, critically reviewed and approved the final manuscript. DC takes responsibility for the paper as a whole.

No funding.

The dataset used and analyzed for the current study is available from the corresponding author on reasonable request.

This study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Institutional Review Board (CE 2020-85) of the French Intensive Care Society on the 27th of November 2020.

Not applicable.

The authors declare that they have no competing interests.Received: 15 December 2020 Accepted: 18 December 2020